Esophagectomy in Patients With Liver Cirrhosis

Esophagectomy in Patients With Liver Cirrhosis - an Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04809870

Enrollment

170

Registered

2021-03-22

Start date

2020-10-01

Completion date

2021-04-10

Last updated

2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Liver Cirrhosis

Keywords

esophagectomy

Brief summary

Retrospective and confounder adjusted comparison of perioperative and longterm outcomes of patients requiring an esophagectomy for esophageal cancer with and without concomitant liver cirrhosis.

Interventions

PROCEDUREsurgery

retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* age ≥ 18 years * primary esophageal cancer with indication for curative treatment * follow up period ≥ 5 years * LC cohort: pre- or intraoperative histological proof of liver cirrhosis

Exclusion criteria

* recurrent esophageal cancer * missing indication for curative treatment of esophageal cancer * esophagectomy for benign esophageal lesions

Design outcomes

Primary

Measure	Time frame
Long-term survival	5 years

Secondary

Measure	Time frame	Description
Anastomotic leakage rate	90 days postoperatively	Rate of endoscopically diagnosed anastomotic leakage
Sepsis rate	90 days postoperatively	Rate of participants with ≥ 2 points in Sepsis-related organ failure (SOFA) score within hospital stay
Renal failure rate	90 days postoperatively	Rate of acute kidney insufficiency (AKI) II-III (AKI Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines)
Major complication	90 days postoperatively	Clavin Dindo ≥ 3
Cardiac complication	90 days postoperatively	cardiac complication requiring pharmacological treatment or intervention and / or ICU surveillance
Chylus fistula rate	90 days postoperatively	Concentration of triglycerides (TG) in drain fluids ≥ 3 times TGs i.s.
Pulmonary complications	90 days postoperatively	Pneumonia requiring antibiotics, ventilatory insufficiency requiring supportive therapy
Hepatic failure rate	90 days postoperatively	Number of participants with clinical diagnosis: coagulopathy, icterus and potentially hepatic encephalopathy

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026